Evidence map›Paper›PMID 41716292›Full record

ArticleEJHaem2026

A Unique Case of Concomitant T-Prolymphocytic Leukemia and B-Cell Acute Lymphoblastic Leukemia.

Viral M Patel, Jonathan Hyak, Soolmaz Laknezhad, Monica Chintapenta, Prapti Patel, Weina Chen, Radhika Kainthla

Abstract read
In one paragraph

Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Viral M PatelDepartment of Internal Medicine Division of Hematology/Oncology University of Texas Southwestern Dallas Texas USA.
Jonathan HyakDepartment of Internal Medicine Division of Hematology/Oncology University of Texas Southwestern Dallas Texas USA.
Soolmaz LaknezhadParkland Health and Hospital System Dallas Texas USA.
Monica ChintapentaParkland Health and Hospital System Dallas Texas USA.
Prapti PatelDepartment of Internal Medicine Division of Hematology/Oncology University of Texas Southwestern Dallas Texas USA.
Weina ChenParkland Health and Hospital System Dallas Texas USA.
Radhika KainthlaDepartment of Internal Medicine Division of Hematology/Oncology University of Texas Southwestern Dallas Texas USA.ORCID https://orcid.org/0000-0003-1636-2113

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T-prolymphocytic leukemia (T-PLL) is a rare lymphoid malignancy with a poor prognosis. B-cell acute lymphoblastic leukemia (B-ALL) also confers a poor prognosis, especially in patients with high-risk features without an option for transplant. Here, we present a case of a patient with T-PLL initially treated with multi-agent chemotherapy who then developed B-ALL, the management strategies, and possible pathogenesis of two concurrent rare malignancies. One proposed mechanism for the development of both hematologic malignancies in this patient is the acquisition of a

Indexed as

alemtuzumabB‐cell acute lymphoblastic leukemiaJAK3KMT2ATCL1T‐prolymphocytic leukemia

Identifiers

PMID41716292
PMCPMC12915108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.